GP practice valuation: frequently asked questions
Australian GP practices are valued using a multiple of normalised EBITDA, adjusted to remove owner-specific costs and one-off items. The multiple reflects practice size, location, billing model, GP tenure and buyer type. No authoritative public dataset of multiples exists. Formal assessment by a qualified valuer or accountant with GP transaction experience is required for a reliable figure.
How is a GP practice valued in Australia?
The standard method is a multiple of normalised EBITDA. Buyers calculate or reconstruct the normalised figure, apply a multiple and adjust for risk factors including practice scale, location, billing model, GP tenure, lease security and buyer category. Published multiple ranges vary widely and no authoritative public dataset exists. Specific valuation guidance requires formal assessment by a qualified valuer or accountant with experience in GP practice transactions. Generic multiple ranges should not be relied on.
Further reading: Financial benchmarks buyers use to assess GP practices
What EBITDA multiple will a buyer apply to my GP practice?
Corporate buyers typically offer 4–6x normalised EBITDA for quality practices. GP group buyers generally pay 3–4x. Internal succession sits lowest at 2.5–3.5x, partly because incoming buyers have less capital and already understand the practice’s weaknesses. Most corporate deals include earnout components tied to post-sale billing continuity and GP retention, meaning the effective multiple received is often lower than the headline figure. No range is reliable without formal assessment of your specific practice.
What is normalised EBITDA and why do buyers use it?
Normalised EBITDA is reported profit adjusted to remove costs specific to the current owner, one-off expenses and non-arm’s-length arrangements. Buyers use it because raw profit figures reflect the owner’s personal financial decisions, not what the practice sustainably earns under new ownership. The normalised figure is what buyers apply a multiple to when pricing a practice. If the seller has not calculated it, the buyer’s due diligence team will, typically on less favourable assumptions.
Further reading: How to normalise EBITDA for GP practice valuation
What expenses can I add back to increase my normalised EBITDA?
Legitimate add-backs include owner salary or superannuation above market rate, personal expenses run through the business (vehicle leases, private travel, family wages in roles not needed post-sale), one-off costs such as legal settlements or non-recurring equipment write-offs, related-party rent above market rate, and genuinely redundant roles. Each add-back must be documented with supporting evidence including BAS statements, invoices and accountant verification, and must be defensible under buyer scrutiny.
Further reading: What counts as a legitimate add-back in EBITDA normalisation
What does not qualify as an EBITDA add-back?
Normal operating costs cannot be added back: staff wages at market rate, rent, utilities, insurance and supplies. Marketing spend that drives patient acquisition cannot be removed if that spend is necessary to maintain revenue. Market-rate salaries for roles the buyer will retain cannot be added back. Costs the owner argues could be reduced under different management, but that are genuinely necessary to run the practice, will be challenged during due diligence and usually rejected.
Further reading: What counts as a legitimate add-back in EBITDA normalisation
How does my clinical income as an owner-GP affect the practice valuation?
Owner-GP billings are personal labour income. They flow through the practice accounts but stop when the owner stops consulting. Buyers separate these billings from maintainable business earnings and replace them with the cost of a tenant GP at the practice’s service fee rate, typically retaining 65–70% for the GP. The higher the owner’s share of total billings, the more deal terms shift toward contingent payments and post-sale retention arrangements.
Further reading: Owner clinical time: separating contribution from profit
How many years of financial records do buyers require?
Buyers and their financiers require at least two, and preferably three, years of lodged and verified tax returns. A single year’s result is not sufficient to confirm earnings stability. The normalised EBITDA statement should cover the same period, with each year’s figures reconciled against BAS and profit and loss statements. Missing or delayed lodgements create timing risk, signal compliance gaps and give buyers a basis for price reduction or withdrawal.
Further reading: How to normalise EBITDA for GP practice valuation
Does a high bulk billing rate reduce my practice value?
Not necessarily. The binary framing of bulk billing as a valuation weakness is no longer reliable. Since November 2025, the Bulk Billing Practice Incentive Program and expanded bulk billing incentives have changed the financial calculus. A practice well-positioned to capture enhanced incentives may have a more defensible revenue base than the same profile would have attracted two years prior. The relevant question is whether the practice demonstrates consistent profitability under the current and foreseeable rebate framework.
Further reading: Financial benchmarks buyers use to assess GP practices
How does the headline multiple differ from the effective price in a GP practice sale?
The headline multiple quoted by a buyer rarely equals the total price the seller receives. Corporate buyers typically state 4–6x EBITDA but attach earnout components tied to post-sale billing continuity and GP retention. If targets are missed, the effective price falls below the headline figure. GP group buyers generally offer lower multiples (3–4x) with fewer contingencies, so the gap between stated and received price tends to be smaller.
How does an earn-out provision work in a GP practice sale?
An earn-out ties part of the purchase price to post-sale performance over an agreed period, typically one to five years. Common metrics include total practice billings, patient retention rates, GP retention and profitability thresholds. The seller receives the deferred payment only if targets are met. If the buyer changes fee structures, loses staff or underinvests post-settlement, the seller’s earn-out can fall short through no fault of their own. Earn-out terms are negotiable and should be reviewed carefully before signing.
Further reading: Owner clinical time: separating contribution from profit
How is a GP practice valued for an internal sale to an existing partner or associate?
Internal sales are typically valued on the same EBITDA basis as external sales, but the multiple applied is often lower. Incoming owners have less capital than corporate buyers and carry more personal risk. Practices valued at 4-5x EBITDA for an external sale may transact at 2.5-3.5x for an internal succession. The structure of the transaction matters as much as the multiple: vendor finance, staged payments, earnouts and profit-share arrangements are all common. The valuation should be prepared by an independent accountant, not agreed informally.
What financial benchmarks do buyers use to assess a GP practice?
Buyers assess GP practices against benchmarks including revenue per FTE GP, EBITDA margin, patient encounters per session, chronic disease management billing rates, bulk billing rate and MyMedicare enrolment rate. They also compare against industry-wide data on cost of clinical services as a percentage of revenue, and against the practice's own historical trend. A practice performing below benchmark on multiple measures is repriced or has conditions attached. Understanding where your practice sits before a buyer does gives you time to improve the position.
Further reading: Financial benchmarks buyers use to assess GP practices